Association of human cathelicidin (hCAP-18/LL-37) gene expression with cardiovascular disease risk factors

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 19, Issue 10, 2009, Pages 720-728

  Benachour, H ^a   Zaiou, M ^a   Samara, A ^a   Herbeth, B ^a   Pfister, M ^a   Lambert, D ^a   Siest, G ^a   Visvikis Siest, S ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Antimicrobial peptides; Body mass index; Cardiovascular diseases; Cathelicidin LL 37; Metabolic syndrome

Indexed keywords

CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE; LIPID; LIPOPROTEIN;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BLOOD; BLOOD CELL COUNT; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; FEMALE; GENE EXPRESSION; GENETICS; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; RISK FACTOR; X CHROMATIN;

ADULT; AGED; ANTHROPOMETRY; BLOOD CELL COUNT; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CATHELICIDINS; FEMALE; GENE EXPRESSION; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPIDS; LIPOPROTEINS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; SEX CHROMATIN;

EID: 70350608319     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2009.01.001     Document Type: Article

References (40)

1. Pickup J.C., Mattock M.B., Chusney G.D., and Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40 (1997) 1286-1292
2. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27 (2004) 813-823
3. Biondi-Zoccai G.G., Abbate A., Liuzzo G., and Biasucci L.M. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 41 (2003) 1071-1077
4. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415 (2002) 389-395
5. Zaiou M., and Gallo R.L. Cathelicidins, essential gene-encoded mammalian antibiotics. J Mol Med 80 (2002) 549-561
6. Bals R., Wang X., Zasloff M., and Wilson J.M. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 95 (1998) 9541-9546
7. Agerberth B., Charo J., Werr J., Olsson B., Idali F., Lindbom L., et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 96 (2000) 3086-3093
8. Gudmundsson G.H., Agerberth B., Odeberg J., Bergman T., and Olsson B. Salcedo. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem 238 (1996) 325-332
9. Cowland J., Johnsen A., and Borregaard N. hCAP-18, a cathelin/pro-bactenecin-like protein of human neutrophil specific granules. FEBS Lett 368 (1995) 173-176
10. Frohm M., Agerberth B., Ahangari G., Stâhle-Bäckdahl M., Lidén S., Wigzell H., et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 272 (1997) 15258-15263
11. Agerberth B., Gunne H., Odeberg J., Kogner P., Boman H.G., and Gudmundsson G.H. FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc Natl Acad Sci USA 92 (1995) 195-199
12. Sørensen O.E., Follin P., Johnsen A.H., Calafat J., Tjabringa G.S., Hiemstra P.S., et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97 (2001) 3951-3959
13. Yang D., Chen Q., Schmidt A.P., Anderson G.M., Wang J.M., Wooters J., et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T-cells. J Exp Med 192 (2000) 1069-1074
14. Scott M.G., Davidson D.J., Gold M.R., Bowdish D., and Hancock R.E. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 169 (2002) 3883-3891
15. Zaiou M. Multifunctional antimicrobial peptides: therapeutic targets in several human diseases. J Mol Med 85 (2007) 317-329
16. Edfeldt K., Agerberth B., Rottenberg M.E., Gudmundsson G.H., Wang X.B., Mandal K., et al. Involvement of the antimicrobial peptide LL-37 in human atherosclerosis. Arterioscler Thromb Vasc Biol 26 (2006) 1551-1557
17. Ciornei C.D., Tapper H., Bjartell A., Sternby N.H., and Bodelsson M. Human antimicrobial peptide LL-37 is present in atherosclerotic plaques and induces death of vascular smooth muscle cells: a laboratory study. BMC Cardiovasc Disord 20 (2006) 49
18. Higazi A.A., Nassar T., Ganz T., Rader D.J., Udassin R., Bdeir K., et al. The alpha-defensins stimulate proteoglycan-dependent catabolism of low-density lipoprotein by vascular cells: a new class of inflammatory apolipoprotein and a possible contributor to atherogenesis. Blood 96 (2000) 1393-1398
19. Joseph G., Tarnow L., Astrup A.S., Hansen T.K., Parving H.H., Flyvbjerg A., et al. Plasma alpha-defensin is associated with cardiovascular morbidity and mortality in type 1 diabetic patients. J Clin Endocrinol Metab 93 (2008) 1470-1475
20. Siest G., Visvikis S., Herbeth B., Gueguen R., Vincent-Viry M., Sass C., et al. Objectives, design and recruitment of a familial and longitudinal cohort for studying gene-environment interactions in the field of cardiovascular risk: the Stanislas cohort. Clin Chem Lab Med 36 (1998) 35-42
21. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
22. Marteau J.B., Mohr S., Pfister M., and Visvikis-Siest S. Collection and storage of human blood cells for mRNA expression profiling: a 15-month stability study. Clin Chem 51 (2005) 1250-1252
23. Liss B. Improved quantitative real-time RT-PCR for expression profiling of individual cells. Nucleic Acids Res 30 (2002) e89
24. Wong M.L., and Medrano J.F. Real-time PCR for mRNA quantification. BioTechniques 39 (2005) 75-85
25. Colditz G.A., Willett W.C., Rotnitzky A., and Manson J.E. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 122 (1995) 481-486
26. Bekri S., Gual P., Anty R., Luciani N., Dahman M., Ramesh B., et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 131 (2006) 788-796
27. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., and Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116 (2006) 3015-3025
28. Dixon J.B., and O'Brien P.E. Obesity and the white blood cell count: changes with sustained weight loss. Obes Surg 16 (2006) 251-257
29. Fontana L., Eagon J.C., Colonna M., and Klein S. Impaired mononuclear cell immune function in extreme obesity is corrected by weight loss. Rejuvenation Res 10 (2007) 41-46
30. Stallone D.D. The influence of obesity and its treatment on the immune system. Nutr Rev 52 (1994) 37-50
31. Srivastava M.D., Thomas A., Srivastava B.I., and Check J.H. Expression and modulation of progesterone induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone. Leuk Lymphoma 48 (2007) 1610-1617
32. Hellström L., Wahrenberg H., Hruska K., Reynisdottir S., and Arner P. Mechanisms behind gender differences in circulating leptin levels. J Intern Med 247 (2000) 457-462
33. Gubern C., López-Bermejo A., Biarnés J., Vendrell J., Ricart W., and Fernández-Real J.M. Natural antibiotics and insulin sensitivity: the role of bactericidal/permeability-increasing protein. Diabetes 55 (2006) 216-224
34. Higazi A.A., Lavi E., Bdeir K., Ulrich A.M., Jamieson D.G., Rader D.J., et al. Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells. Blood 89 (1997) 4290-4298
35. López-Bermejo A., Chico-Julià B., Castro A., Recasens M., Esteve E., Biarnés J., et al. Alpha defensins 1, 2, and 3: potential roles in dyslipidemia and vascular dysfunction in humans. Arterioscler Thromb Vasc Biol 27 (2007) 1166-1171
36. Barnathan E.S., Raghunath P.N., Tomaszewski J.E., Ganz T., and Cines D.B. Higazi A al-R. Immunohistochemical localization of defensin in human coronary vessels. Am J Pathol 150 (1997) 1009-1020
37. Dorschner R.A., Pestonjamasp V.K., Tamakuwala S., Ohtake T., Rudisill J., Nizet V., et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol 117 (2001) 91-97
38. Frohm M., Agerberth B., Ahangari G., Ståhle-Bäckdahl M., Lidén S., Wigzell H., et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 272 (1997) 15258-15263
39. Frohm M., Sandstedt B., Sørensen O., Weber G., Borregaard N., and Ståhle-Bäckdahl M. The human cationic anti-microbial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect Immun 67 (1999) 2561-2566
40. Malm J., Sørensen O., Persson T., Frohm-Nilsson M., Johansson B., Bjartell A., et al. The human cationic anti-microbial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa. Infect Immun 68 (2000) 4297-4302